ANAB Stock Forecast: AnaptysBio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$47
−1.62% on the day

The 8 Wall Street analysts covering AnaptysBio, Inc. hold a median 12-month price target of $80 — +70.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 90 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
90/ 100
Median analyst target
$80
Analysts covering
8
Revenue$25.6M−8.0% y/y
Operating income−$34.6M
Net income−$52.9M
Free cash flow−$25.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
+2.6%
YTD
+44.3%
1Y
+85.7%
From 52W high
−33.2%
From 52W low
+85.7%
$25
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores AnaptysBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
90/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
91
Growth
88
Momentum
82
Issuance
78
Quality
72
Revisions
52
Accruals
31

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (31): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ANAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26ANABHigh $140Median $80Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$60
Low
$80
Median
$140
High

The green dot is the last close — the median target sits +70.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
30 Sept 2026JP MorganMaintainsOverweight$70 → $60
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$95
23 Sept 2026Leerink PartnersMaintainsOutperform$90 → $81
25 Aug 2026TD CowenMaintainsBuy$75 → $70
24 Aug 2026HC Wainwright & Co.ReiteratesBuy$95
10 June 2026HC Wainwright & Co.AssumesBuy$95
13 May 2026BarclaysMaintainsOverweight—
13 May 2026UBSMaintainsBuy—
4 May 2026Piper SandlerMaintainsOverweight—
28 Apr 2026Leerink PartnersMaintainsOutperform—
22 Apr 2026BarclaysMaintainsOverweight—
21 Apr 2026UBSMaintainsBuy—
31 Mar 2026Piper SandlerMaintainsOverweight—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026UBSMaintainsBuy—
12 Mar 2026WedbushMaintainsOutperform—
9 Mar 2026Truist SecuritiesMaintainsHold—
5 Mar 2026StifelMaintainsBuy—
4 Mar 2026BarclaysMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ANAB.

Market Radar

This page is one stock. Monday covers all of them.

ANAB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ANAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, AnaptysBio, Inc. returned +85.7% against +6.9% for the S&P 500, dividends included.

ANAB vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26ANABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.3×

Cheaper than 81% of US stocks

Price / sales
23.4×

Cheaper than 7% of US stocks

Price / book
68.1×

Cheaper than 1% of US stocks

EV / EBITDA
168.5×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−74.4%

Higher than 6% of US stocks

Gross margin
—
Operating margin
15.0%

Higher than 72% of US stocks

Net margin
—
Returns & dividend
Return on equity
−35.6%

Higher than 26% of US stocks

Return on assets
−3.6%

Higher than 34% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AnaptysBio, Inc. has a market value of $1.4B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 31 Mar 2026: $232.4M. The latest quarter shrank 8.0% year on year.

  • Net income over the same four quarters: −$26.8M, a −11.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.08.

  • Free cash flow in the twelve months to 31 Mar 2026: $4.4M, after $69K of capital spending.

  • AnaptysBio, Inc. spent $64.2M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 29.0M.

  • Trailing P/E: 7.3×; forward P/E: 10.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • AnaptysBio, Inc. employs 104 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ANAB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANABAnaptysBio, Inc.$1.4B90
TYRATyra Biosciences, Inc.$1.4B28
RAPPRapport Therapeutics, Inc.$1.4B66
ADRXADARx Pharmaceuticals, Inc.$1.4B0
NTLAIntellia Therapeutics, Inc.$1.4B27
KLRAKailera Therapeutics, Inc.$1.4B3
DMRADamora Therapeutics, Inc.$1.4B44

Take a look at ANAB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own AnaptysBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ANAB

What is the ANAB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering AnaptysBio, Inc. have a median 12-month price target of $80, with estimates ranging from $60 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANAB stock a buy right now?

Of the 8 analysts covering AnaptysBio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AnaptysBio, Inc. 90 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANAB?

As at 21 Nov 2026, AnaptysBio, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ANAB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +70.5% from the last close, and Ticker Nerd's factor model ranks AnaptysBio, Inc. 90 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANAB stock forecast for 2030?

No analyst covering AnaptysBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $140 over the next 12 months.

How has ANAB stock performed over the past year?

AnaptysBio, Inc. returned +85.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AnaptysBio, Inc. do?

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets.

Company

About AnaptysBio, Inc.

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.

CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.anaptysbio.com